Category Archives: Uncategorized

Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Oncolix, for conducting clinical studies for its analogue protein, Prolanta, to treat ovarian cancer. The trials will be conducted in the … Continue reading →

Below, we are re-publishing with permission the press-release issued by Noxopharm Limited on the 5th of April 2018      • Multi-national study testing ability of NOX66 to enhance radiotherapy      • First cohort of patients treated      • Direct … Continue reading →

In one of the recent issues of the Journal of the American College of Cardiology, Professor Stuart Pocock and colleagues discussed controversies in reporting clinical trial results.  Prof. Pocock is a well-known biostatistician from the Department of Medical Statistics at … Continue reading →

This study aimed to illustrate how sponsors should measure quality of clinical trials and identify the various drivers of performance.  It was able to actually quantify the magnitude of the relationship between each of the drivers of performance and quality … Continue reading →

“Quality is never an accident. It is always the result of intelligent effort” (John Ruskin 1819-1900). Quality is an abstract concept and a term with which we are all familiar and tend to take for granted.  It is something to … Continue reading →

In Part 1 we looked at the guidelines [1] for the requirement in India to make AV-recordings of the investigator(s) and patients (and any necessary witnesses/representatives) during the consent process and potential implications [2]. So how, in practice, has this … Continue reading →